drugset / Trial / NCT07470073
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
Phase 0
Recruiting
18 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
This study is a single arm, open label, dose exploring clinical trial to evaluate the safety, efficacy, cellular metabolic dynamics, and pharmacodynamics of ct1190b cells in relapsed / refractory B-cell acute lymphoblastic leukemia.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2027-12-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT1190B | Cell therapy | 3e+06 cells/kg | — |
| Subject | CT1190B | Cell therapy | 6e+06 cells/kg | — |
| Subject | CT1190B | Cell therapy | 3e+08 cells | — |
| Subject | CT1190B | Cell therapy | 4.5e+08 cells | — |
| Subject | CT1190B | Cell therapy | 6e+08 cells | — |